Thompson Siegel & Walmsley LLC Sells 61,370 Shares of Laboratory Co. of America Holdings (NYSE:LH)

Thompson Siegel & Walmsley LLC reduced its stake in Laboratory Co. of America Holdings (NYSE:LH) by 16.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 318,747 shares of the medical research company’s stock after selling 61,370 shares during the period. Laboratory Co. of America accounts for approximately 1.1% of Thompson Siegel & Walmsley LLC’s investment portfolio, making the stock its 27th biggest position. Thompson Siegel & Walmsley LLC owned approximately 0.38% of Laboratory Co. of America worth $71,234,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. O Shaughnessy Asset Management LLC increased its stake in shares of Laboratory Co. of America by 4.3% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 4,890 shares of the medical research company’s stock valued at $1,068,000 after purchasing an additional 203 shares during the last quarter. CreativeOne Wealth LLC acquired a new position in shares of Laboratory Co. of America during the 1st quarter valued at $282,000. EP Wealth Advisors LLC bought a new position in shares of Laboratory Co. of America during the 1st quarter worth about $211,000. Advisors Asset Management Inc. boosted its holdings in Laboratory Co. of America by 99.3% in the first quarter. Advisors Asset Management Inc. now owns 2,178 shares of the medical research company’s stock worth $476,000 after acquiring an additional 1,085 shares in the last quarter. Finally, Toronto Dominion Bank grew its position in Laboratory Co. of America by 78.2% in the 1st quarter. Toronto Dominion Bank now owns 48,615 shares of the medical research company’s stock valued at $10,620,000 after purchasing an additional 21,339 shares during the period. 95.94% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

LH has been the subject of a number of recent analyst reports. Bank of America upped their price objective on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. Piper Sandler increased their price target on shares of Laboratory Co. of America from $235.00 to $240.00 and gave the company a “neutral” rating in a research report on Monday, October 28th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Laboratory Co. of America from $220.00 to $230.00 and gave the stock a “hold” rating in a research report on Friday, August 2nd. Robert W. Baird upped their price objective on Laboratory Co. of America from $282.00 to $289.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Finally, Barclays raised their target price on Laboratory Co. of America from $234.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $255.92.

Laboratory Co. of America Stock Up 0.7 %

LH opened at $237.85 on Thursday. The business’s fifty day simple moving average is $225.35 and its 200 day simple moving average is $216.49. Laboratory Co. of America Holdings has a 52 week low of $191.97 and a 52 week high of $247.99. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.66. The stock has a market cap of $19.89 billion, a PE ratio of 46.01, a P/E/G ratio of 1.94 and a beta of 1.05.

Laboratory Co. of America (NYSE:LH) last released its earnings results on Thursday, October 24th. The medical research company reported $3.50 EPS for the quarter, beating the consensus estimate of $3.48 by $0.02. The company had revenue of $3.28 billion for the quarter, compared to analyst estimates of $3.26 billion. Laboratory Co. of America had a net margin of 3.43% and a return on equity of 15.27%. The firm’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the firm earned $3.38 EPS. As a group, research analysts expect that Laboratory Co. of America Holdings will post 14.53 earnings per share for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 13th. Stockholders of record on Tuesday, November 26th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.21%. The ex-dividend date of this dividend is Tuesday, November 26th. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 55.71%.

Insider Activity at Laboratory Co. of America

In other news, Director Kerrii B. Anderson sold 1,000 shares of the company’s stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $230.00, for a total transaction of $230,000.00. Following the completion of the transaction, the director now directly owns 13,722 shares of the company’s stock, valued at approximately $3,156,060. This represents a 6.79 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Adam H. Schechter sold 6,189 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $243.47, for a total value of $1,506,835.83. Following the transaction, the chief executive officer now owns 87,441 shares of the company’s stock, valued at approximately $21,289,260.27. This represents a 6.61 % decrease in their position. The disclosure for this sale can be found here. 0.85% of the stock is currently owned by company insiders.

Laboratory Co. of America Profile

Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.